ABOS

Acumen Pharmaceuticals, Inc. ABOS

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode ABOS INO IRD AGEN ALEC SEER MCRB FATE VTGN SPRO
6M 79.82 % 13.75 % 127.88 % -27.63 % -5.96 % -10.15 % 111.60 % -8.87 % 86.44 % -19.47 %
YTD 10.81 % 25.00 % 70.24 % 20.39 % -24.87 % -22.10 % -5.93 % -36.87 % 32.53 % 112.50 %
1Y 4.06 % 5.81 % 114.50 % 31.45 % -28.28 % -26.81 % -10.84 % -43.50 % 77.42 % 114.49 %
3Y -64.16 % -89.47 % 66.28 % -92.22 % -84.34 % -71.01 % -86.20 % -91.36 % -2.22 % 36.61 %
5Y -89.80 % -98.18 % 66.28 % -94.85 % -90.44 % -97.34 % -96.72 % -98.77 % -82.33 % -87.50 %
10Y -89.80 % -97.14 % 66.28 % -95.92 % -92.11 % -96.79 % -98.19 % -67.71 % -97.28 % -80.04 %
From the beginning -89.80 % -99.68 % 66.28 % -99.95 % -92.11 % -96.79 % -98.46 % -82.93 % -99.70 % -80.04 %

Dividend

Inovio Pharmaceuticals, Inc.

Spero Therapeutics, Inc.